Market News & Trends
XBiotech Engages in Research for Heart Attack Antibody Therapy
XBiotech Inc., developer of True Human™ therapeutic antibodies, announced today the signing of a Material Transfer Agreement (MTA) with Brigham and Women’s Hospital and Massachusetts…
Merck’s Zepatier Will Threaten the Dominance of Gilead’s Harvoni in Hepatitis C Market
The introduction of Merck and Co.’s recently-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market long-dominated by Gilead. The…
Infusion Pumps That Sense The Drug Flow - And Even Your Heartbeat - In It
By: Jonas Horn, Application Expert, Medical Liquid Flow Sensors Sensor technology takes infusion pumps to the next level by making failure detection reliable, even…
Sigmoid Pharma Announces Acquisition of Freund Pharmatec Ltd.
Sigmoid Pharma Ltd recently announced it has entered into an agreement to acquire Freund Pharmatec Ltd. Through this acquisition, Sigmoid will acquire 100% ownership of…
Portola Pharmaceuticals Enters Licensing Agreements Worth Up to $120 Million
Portola Pharmaceuticals recently announced it has licensed lead development and commercial rights to its investigational agent andexanet alfa in Japan to Bristol-Myers Squibb Company and…
Enable Injections & Flex Partner for Production of Wearable High-Volume Injectors
Enable Injections Inc. recently announced it has entered into a product development and manufacturing partnership with Flex. As part of the deal, Enable Injections and…
Dipexium Reaches 75% Enrollment Milestone in Pivotal Phase III Trials
Dipexium Pharmaceuticals, Inc. recently announced its OneStep-1 and OneStep-2 pivotal Phase III clinical trials have reached the 75% enrollment milestone, in the aggregate, with each…
Albumedix & Eleven Biotherapeutics Announce Albumin Variant Technology Agreement
Eleven Biotherapeutics, Inc. and Albumedix recently announced they have entered into an agreement that will see Albumedix acquire Eleven’s proprietary Supermin albumin variant assets. Albumedix…
Lonza to Build Capabilities for Drug Product Development Services, Enabling One-Stop-Shop Solutions
Lonza recently announced that its Pharma & Biotech segment is expanding its footprint to offer customers a complete portfolio of development and manufacturing services for…
Sernova Announces Agreement With CCRM to Produce Specialized Cells for Diabetes Treatment
Sernova Corp recently announced it has entered into a service agreement with the Centre for Commercialization of Regenerative Medicine (CCRM) to establish, optimize, and validate…
Noxilizer Announces New Senior Vice President & CFO
Noxilizer, Inc., the company advancing a room temperature, NO2-based sterilization and decontamination process for biopharmaceutical and medical device manufacturers recently announced David A. Theil as…
AbCellera & Merck Sign Novel Therapeutic Antibody Discovery Collaboration
AbCellera recently announced a new collaboration with Merck, known as MSD outside the United States and Canada, through a subsidiary, to generate antibodies against an…
Catalent & Cerenis Therapeutics Announce Phase III Trial of CER-001
Catalent Pharma Solutions recently announced that Cerenis Therapeutics has advanced its leading clinical candidate, CER-001, into Phase III clinical studies across Europe and North America.…
Fibrocell Science Highlights Recent Pipeline Accomplishments
Fibrocell Science, Inc. recently highlighted several recent accomplishments related to the continued advancement of the company’s pipeline. “Recently, Fibrocell has made significant progress across our…
Trillium Therapeutics Acquires Fluorinov Pharma
FACIT has announced that Trillium Therapeutics Inc. has acquired all of the outstanding shares of privately held Fluorinov Pharma Inc., a FACIT portfolio company. The…
Global Orphan Drug Market to Gain Almost $68 Billion by 2019; Favorable Legislation Spurring R&D
Growing competition, new technologies, improved gene therapies, and favorable legislation and incentives have led the global orphan drug market to experience a significant increase in…
RNAi Therapeutics Holds Therapeutic Promise for Unmet Conditions
Ribonucleic acid interference (RNAi) mechanisms and technologies are being extensively explored in biological applications in order to silence mRNA’s encoding proteins and to develop appropriate…
Pharma Companies Must Assess Real-World Evidence to Keep Up With Shifts in the Global Market Access Landscape
As the overall costs of drugs continue to increase and pricing pressures shift the dynamics of the healthcare market, pharmaceutical companies must analyze real-world trends…
GeneOne Life Science & Inovio Pharmaceuticals to Collaborate on Zika Virus Vaccine Development
GeneOne Life Science recently announced the initiation of a collaborative research program with Inovio Pharmaceuticals to test and advance a DNA-based vaccine for preventing and…
Polyganics & MicroAire Sign Exclusive Distribution Agreement
Polyganics recently announced it has signed an exclusive distribution agreement with its strategic partner MicroAire Surgical Instruments LLC for the company’s entire peripheral nerve repair…
